NASDAQ · XENE
Healthcare · Biotechnology
$61.93
Down-$1.86 (-2.92%)
Updated Aug 28, 2026, 8:59 AM
SID Score
6.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
XENE closed at $61.93 after 21 trading sessions, down 3.52% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $63.13 | $63.775 | $61.85 | $61.93 | 586.97K |
| Aug 26, 2026 | $60.42 | $64.81 | $59.26 | $63.79 | 1.3M |
| Aug 25, 2026 | $61.01 | $61.67 | $60.26 | $60.42 | 418.01K |
| Aug 24, 2026 | $60.77 | $61.045 | $60.00 | $60.56 | 628.83K |
| Aug 21, 2026 | $60.45 | $61.57 | $59.7257 | $60.77 | 792.93K |
| Aug 20, 2026 | $61.41 | $62.51 | $59.27 | $59.73 | 627.24K |
| Aug 19, 2026 | $64.71 | $64.93 | $62.18 | $62.32 | 558.96K |
| Aug 18, 2026 | $61.28 | $63.855 | $61.28 | $63.18 | 914.93K |
| Aug 17, 2026 | $61.98 | $62.77 | $61.2315 | $62.36 | 689.72K |
| Aug 14, 2026 | $63.60 | $63.90 | $61.63 | $62.35 | 921.88K |
| Aug 13, 2026 | $65.66 | $65.70 | $63.73 | $64.23 | 496.37K |
| Aug 12, 2026 | $63.49 | $65.415 | $63.015 | $65.26 | 778.19K |
| Aug 11, 2026 | $64.50 | $64.95 | $62.82 | $63.22 | 665.65K |
| Aug 10, 2026 | $62.98 | $64.245 | $62.85 | $64.23 | 510.7K |
| Aug 7, 2026 | $63.00 | $64.49 | $62.63 | $63.36 | 720.24K |
| Aug 6, 2026 | $64.50 | $65.49 | $63.91 | $64.55 | 435.01K |
| Aug 5, 2026 | $64.74 | $66.40 | $63.995 | $64.30 | 617.25K |
| Aug 4, 2026 | $63.07 | $64.31 | $62.43 | $64.01 | 639.26K |
| Aug 3, 2026 | $63.21 | $63.325 | $61.16 | $62.26 | 540.7K |
| Jul 31, 2026 | $63.94 | $64.505 | $62.56 | $62.67 | 736.96K |
| Jul 30, 2026 | $62.93 | $64.555 | $61.86 | $64.19 | 541.55K |
The latest Smart Investors Daily articles mentioning XENE.
XENE research
Company profile and research snapshot.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Outperform | — |
| May 27, 2026 | JP Morgan | Overweight | — |
| May 12, 2026 | JP Morgan | Overweight | — |
| May 8, 2026 | Needham | Buy | — |
| May 8, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
ChartMill · Aug 13, 2026
XENE (Xenon Pharmaceuticals) scores 9/10 on trend and setup quality, showing strong consolidation near a breakout with defined entry and stop levels.
SeekingAlpha · Aug 11, 2026
Benzinga · Aug 7, 2026
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $82 to $81.
SeekingAlpha · Aug 7, 2026
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsColleen Alabiso - Senior Vice President of Corporate...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XENE.
